<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERLOTINIB</span><br/>(er-lo'ti-nib)<br/><span class="topboxtradename">Tarceva<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">tyrosine kinase inhibitor; epidermal growth factor receptor inhibitor</span><br/><b>Prototype: </b>Gefitinib<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg, 150 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Erlotinib is a human epidermal growth factor receptor type 1 (HER1/EGFR) inhibitor. Antitumor action of erlotinib is believed
         to be due to inhibition of EGFR present on the cell surface of both normal and cancer cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibition of EGFR in cancer cells diminishes their capacity for cell proliferation, cell survival, and decreases metastases.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least
         one prior chemotherapy regimen.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Pancreatic cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to erlotinib; pregnancy (category D); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic dysfunction, interstitial pulmonary disease (interstitial pneumonia, pneumonitis, alveolitis); myelosuppression; ocular
         toxicities (corneal ulcer, eye pain). Concurrent use of ketoconazole and other strong CYP3A4 inhibitors (e.g., atazanavir,
         clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and
         voriconazole).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic NonSmall Cell Lung Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg once daily at least 1 h before or 2 h after meals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at least 1 h before or 2 h after eating.</li>
<li>Store at 1530° C (5986° F). Keep container tightly closed. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Infection. <span class="typehead">GI<b></b>
         			:</span>
<span class="speceff-common">Diarrhea</span>
<i>,</i> anorexia, <span class="speceff-common">fatigue,</span> nausea, vomiting, stomatitis, abdominal pain. <span class="typehead">Metabolic<b></b>
         			:</span> Increased LFTs. <span class="typehead">Respiratory<b></b>
         			:</span>
<span class="speceff-common">Dyspnea</span>
<i>, </i>cough, <span class="speceff-life">interstitial lung disease (sometimes fatal)</span>. <span class="typehead">Skin<b></b>
         			:</span>
<span class="speceff-common">Acneiform rash</span>
<i>,</i> pruritus, dry skin. <span class="typehead">Special Senses:</span> Conjunctivitis, dry eyes. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,
         troleandomycin, voriconazole</b> may increase erlotinib levels and toxicity; <b>rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital</b> may decrease erlotinib levels. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease erlotinib levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60% absorbed orally; food can increase to 100%. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination<b></b>
         			:</span> Primarily excreted in feces (83%). <span class="typehead">Half-Life:</span> 36.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely changes in pulmonary function.</li>
<li>Withhold drug and notify physician for acute onset of new or progressive pulmonary symptoms (e.g., dyspnea, cough, or fever)
            or significant changes in liver functions as indicated by elevated transaminases, bilirubin, and alkaline phosphatase.
         </li>
<li>Lab tests: periodic LFTs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: severe or persistent diarrhea, nausea, anorexia, or vomiting; onset or worsening of
            unexplained shortness of breath or cough; eye irritation.
         </li>
<li>Monitor closely PT/INR values with concurrent warfarin therapy.</li>
<li>Women should use effective means to avoid pregnancy while taking this drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>